AstraZeneca said on Friday that safety data on roxadustat underpinned the British drugmaker’s hopes for the anemia drug to become a standard treatment for patients with kidney disease.
This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.
Leave a Reply